U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. Agenda - Workshop on Recombinant Protein-based COVID-19 Vaccines
  1. FDA Meetings, Conferences and Workshops

Agenda - Workshop on Recombinant Protein-based COVID-19 Vaccines

April 27th, 2023, 9AM – 1 PM EDT

Recombinant Protein-Based COVID-19 Vaccines Workshop Event Page

Time Speaker Subject
9:00 AM – 9:05 AM Peter Marks, CBER OD, FDA

Welcome Remarks
9:05 AM – 9:20 AM Robert Johnson, BARDA

Pandemic preparedness, target product profile, timelines, and the need for continued investment
9:20 AM – 9:35 AM Natalie Thornburg, CDC

Epidemiology, disease burden, continued need for COVID-19 vaccines
9:35 AM – 10:00 AM John Beigel, NIH

Features of novel vaccines, need for next generation vaccines
10:00 AM – 10:20 AM Presentation – Novavax, Inc.
Filip Dubosky, Rick Crowley

Recombinant COVID-19 vaccines
10:20 AM – 10:40 AM

Presentation – Sanofi
Roman Chicz

Recombinant COVID-19 vaccines
10:40 AM – 11:00 AM Presentation – SK bioscience
Harry Kleanthous

Recombinant COVID-19 vaccines
11:00 AM – 11:20 PM Presentation – Dyadic
Mark Emalfarb

Recombinant COVID-19 vaccines
11:20 AM – 11:40 AM Presentation – Biological E, Limited
Vikram Parakdar 

Recombinant COVID-19 vaccines
11:40 AM – 12:00 PM Presentation – Intravacc
Dinja Oosterhoff

Recombinant COVID-19 vaccines
12:00 PM – 12:10 PM Break

Break
12:10 PM – 12:55 PM Frank Arnold, BARDA
Jerry Weir, FDA
Joel Straus, BIO
Dave Robinson, BMGF
Adam Hacker, CEPI

Panel Discussion
Moderated by David Kaslow
“Overcoming challenges to address strain updates and pandemic readiness”.
12:55 PM – 1:00 PM David Kaslow

Closing

 

Back to Top